<p>Stoke Therapeutics, Inc.（纳斯达克代码：STOK - 免费报告）- HC Wainwright 在 12 月 15 日（星期一）发布的报告中上调了对 Stoke Therapeutics 2027 财年每股收益（EPS）的预期。HC Wainwright 的分析师 A. Ghosh 现在预计该公司将发布每股收益（$2.08），高于之前的预期（$2.41）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 50.00 美元。Stoke Therapeutics 当前全年的共识预期每股收益为（$2.01）。HC Wainwright 还对 Stoke Therapeutics 2028 财年的每股收益预期为（$0.66），2029 财年的每股收益预期为$1.81。</p>
<p>获取 <strong>Stoke Therapeutics</strong> 的提醒：</p>
<p>其他几家研究公司也最近发布了关于 STOK 的报告。瑞银集团在周一的研究报告中将 Stoke Therapeutics 的目标价设定为 50.00 美元。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 11 月 5 日的研究报告中重申了 “买入” 评级，并将 Stoke Therapeutics 的目标价设定为 39.00 美元。Needham &amp; Company LLC 在 10 月 10 日的报告中将 Stoke Therapeutics 的目标价从 22.00 美元上调至 35.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的目标价从 22.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。两位研究分析师对该股票给予强烈买入评级，六位给予买入评级，两位对该公司的股票给予持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，共识目标价为 34.78 美元。</p>
<p><strong>查看我们最新的 STOK 股票报告</strong></p>
<h2>Stoke Therapeutics 股价上涨 1.9%</h2>
<p>STOK 股票在周三开盘价为 33.61 美元。该公司的 50 日移动平均价格为 30.10 美元，200 日移动平均价格为 21.13 美元。该股票的市值为 19.2 亿美元，市盈率为 50.16，贝塔值为 1.14。Stoke Therapeutics 的 12 个月低点为 5.35 美元，12 个月高点为 38.69 美元。</p>
<p>Stoke Therapeutics（纳斯达克代码：STOK - 获取免费报告）在 11 月 4 日（星期二）发布了其财报。该公司报告的每股收益为（$0.65），低于共识预期的（$0.54）$0.11。Stoke Therapeutics 的净利润率为 19.73%，股本回报率为 13.28%。该公司在本季度的收入为 1063 万美元，而分析师的预期为 606 万美元。</p>
<h2>机构投资者对 Stoke Therapeutics 的看法</h2>
<p>一些机构投资者最近调整了对 STOK 的持股。先锋集团在第三季度将其在 Stoke Therapeutics 的持股增加了 7.4%。先锋集团现在拥有 3163874 股该公司的股票，价值 74351000 美元，此前在该期间内又购买了 217616 股。Marshall Wace LLP 在第二季度将其在 Stoke Therapeutics 的持股增加了 7.9%。Marshall Wace LLP 现在拥有 2300554 股该公司的股票，价值 26111000 美元，此前在该期间内又收购了 168771 股。Siren L.L.C.在第一季度将其在 Stoke Therapeutics 的持股增加了 12.4%。Siren L.L.C.现在拥有 2247347 股该公司的股票，价值 14945000 美元，此前在上个季度又收购了 247347 股。高盛集团在第一季度将其在 Stoke Therapeutics 的持股增加了 21.4%。高盛集团现在拥有 1662039 股该公司的股票，价值 11053000 美元，此前在上个季度又购买了 293072 股。最后，Polar Capital Holdings Plc 在第三季度将其在 Stoke Therapeutics 的持股增加了 49.8%。Polar Capital Holdings Plc 现在拥有 1323470 股该公司的股票，价值 31102000 美元，此前在该期间内又收购了 439824 股。</p>
<h2>内部活动</h2>
<p>在其他消息中，内部人士 Barry Ticho 在 12 月 5 日（星期五）出售了 3662 股该公司的股票。股票以平均价格 31.34 美元出售，总价值为 114767.08 美元。交易后，该内部人士直接持有该公司 19798 股股票，价值约 620469.32 美元。这代表其持股减少了 15.61%。该出售在 SEC 的法律文件中披露，可以通过此超链接访问。此外，首席法律顾问 Jonathan Allan 在 12 月 8 日（星期一）出售了 3978 股该股票。该股票以平均价格 32.28 美元出售，总交易额为 128409.84 美元。交易后，首席法律顾问直接持有该公司 11831 股股票，价值 381904.68 美元。该交易使其持股减少了 25.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 182166 股公司股票，价值 5136957 美元。公司内部人士持有公司股票的 9.50%。</p>
<h2>Stoke Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Stoke Therapeutics, Inc.是一家早期阶段的生物制药公司，致力于开发治疗美国严重遗传疾病根本原因的药物。该公司利用其专有的核基因输出靶向增强技术，开发反义寡核苷酸，以选择性恢复蛋白质水平。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Stoke Therapeutics</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>如何投资 FAANG 股票</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RPSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RPSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Stoke Therapeutics 吗？</h2>
<p>在考虑 Stoke Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Stoke Therapeutics 并不在名单上。</p>
<p>虽然 Stoke Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

STOK

<p>HC Wainwright 将 Stoke Therapeutics 的 2027 财年每股收益预期从 ($2.41) 上调至 ($2.08)，并维持 “买入” 评级，目标价为 $50.00。其他分析师也发布了积极的评级和目标价。STOK 股票开盘价为 $33.61，市值为 19.2 亿美元。机构投资者增加了持股。内部人士 Barry Ticho 最近出售了部分股份</p>

<p>Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Monday, December 15th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($2.08) for the year, up from their prior estimate of ($2.41). HC Wainwright has a &#34;Buy&#34; rating and a $50.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics' FY2028 earnings at ($0.66) EPS and FY2029 earnings at $1.81 EPS.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc.（纳斯达克代码：STOK - 免费报告）- HC Wainwright 在 12 月 15 日（星期一）发布的报告中上调了对 Stoke Therapeutics 2027 财年每股收益（EPS）的预期。HC Wainwright 的分析师 A. Ghosh 现在预计该公司将发布每股收益（$2.08），高于之前的预期（$2.41）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 50.00 美元。Stoke Therapeutics 当前全年的共识预期每股收益为（$2.01）。HC Wainwright 还对 Stoke Therapeutics 2028 财年的每股收益预期为（$0.66），2029 财年的每股收益预期为$1.81。</p>
</div><p>Get <strong>Stoke Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Stoke Therapeutics</strong> 的提醒：</p>
</div><p>Several other research firms have also recently issued reports on STOK. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, November 5th. BTIG Research reaffirmed a &#34;buy&#34; rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Needham &amp; Company LLC upped their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a &#34;buy&#34; rating in a report on Friday, October 10th. Finally, Wedbush increased their price objective on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and a consensus price target of $34.78.</p>
<div class="lb-trans"><p>其他几家研究公司也最近发布了关于 STOK 的报告。瑞银集团在周一的研究报告中将 Stoke Therapeutics 的目标价设定为 50.00 美元。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 11 月 5 日的研究报告中重申了 “买入” 评级，并将 Stoke Therapeutics 的目标价设定为 39.00 美元。Needham &amp; Company LLC 在 10 月 10 日的报告中将 Stoke Therapeutics 的目标价从 22.00 美元上调至 35.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的目标价从 22.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。两位研究分析师对该股票给予强烈买入评级，六位给予买入评级，两位对该公司的股票给予持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，共识目标价为 34.78 美元。</p>
</div><p><strong>View Our Latest Stock Report on STOK</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 STOK 股票报告</strong></p>
</div><h2>Stoke Therapeutics Trading Up 1.9%</h2>
<div class="lb-trans"><h2>Stoke Therapeutics 股价上涨 1.9%</h2>
</div><p>Shares of STOK stock opened at $33.61 on Wednesday. The company's 50-day moving average price is $30.10 and its 200-day moving average price is $21.13. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 50.16 and a beta of 1.14. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69.</p>
<div class="lb-trans"><p>STOK 股票在周三开盘价为 33.61 美元。该公司的 50 日移动平均价格为 30.10 美元，200 日移动平均价格为 21.13 美元。该股票的市值为 19.2 亿美元，市盈率为 50.16，贝塔值为 1.14。Stoke Therapeutics 的 12 个月低点为 5.35 美元，12 个月高点为 38.69 美元。</p>
</div><p>Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to analysts' expectations of $6.06 million.</p>
<div class="lb-trans"><p>Stoke Therapeutics（纳斯达克代码：STOK - 获取免费报告）在 11 月 4 日（星期二）发布了其财报。该公司报告的每股收益为（$0.65），低于共识预期的（$0.54）$0.11。Stoke Therapeutics 的净利润率为 19.73%，股本回报率为 13.28%。该公司在本季度的收入为 1063 万美元，而分析师的预期为 606 万美元。</p>
</div><h2>Institutional Investors Weigh In On Stoke Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Stoke Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of STOK. Vanguard Group Inc. raised its holdings in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock valued at $74,351,000 after buying an additional 217,616 shares during the period. Marshall Wace LLP boosted its holdings in Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock valued at $26,111,000 after acquiring an additional 168,771 shares during the period. Siren L.L.C. grew its position in Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock valued at $14,945,000 after acquiring an additional 247,347 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Finally, Polar Capital Holdings Plc increased its position in shares of Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock worth $31,102,000 after acquiring an additional 439,824 shares during the period.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 STOK 的持股。先锋集团在第三季度将其在 Stoke Therapeutics 的持股增加了 7.4%。先锋集团现在拥有 3163874 股该公司的股票，价值 74351000 美元，此前在该期间内又购买了 217616 股。Marshall Wace LLP 在第二季度将其在 Stoke Therapeutics 的持股增加了 7.9%。Marshall Wace LLP 现在拥有 2300554 股该公司的股票，价值 26111000 美元，此前在该期间内又收购了 168771 股。Siren L.L.C.在第一季度将其在 Stoke Therapeutics 的持股增加了 12.4%。Siren L.L.C.现在拥有 2247347 股该公司的股票，价值 14945000 美元，此前在上个季度又收购了 247347 股。高盛集团在第一季度将其在 Stoke Therapeutics 的持股增加了 21.4%。高盛集团现在拥有 1662039 股该公司的股票，价值 11053000 美元，此前在上个季度又购买了 293072 股。最后，Polar Capital Holdings Plc 在第三季度将其在 Stoke Therapeutics 的持股增加了 49.8%。Polar Capital Holdings Plc 现在拥有 1323470 股该公司的股票，价值 31102000 美元，此前在该期间内又收购了 439824 股。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, insider Barry Ticho sold 3,662 shares of the company's stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.34, for a total value of $114,767.08. Following the transaction, the insider directly owned 19,798 shares in the company, valued at approximately $620,469.32. This represents a 15.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total transaction of $128,409.84. Following the transaction, the general counsel directly owned 11,831 shares of the company's stock, valued at $381,904.68. The trade was a 25.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 182,166 shares of company stock valued at $5,136,957. Company insiders own 9.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Barry Ticho 在 12 月 5 日（星期五）出售了 3662 股该公司的股票。股票以平均价格 31.34 美元出售，总价值为 114767.08 美元。交易后，该内部人士直接持有该公司 19798 股股票，价值约 620469.32 美元。这代表其持股减少了 15.61%。该出售在 SEC 的法律文件中披露，可以通过此超链接访问。此外，首席法律顾问 Jonathan Allan 在 12 月 8 日（星期一）出售了 3978 股该股票。该股票以平均价格 32.28 美元出售，总交易额为 128409.84 美元。交易后，首席法律顾问直接持有该公司 11831 股股票，价值 381904.68 美元。该交易使其持股减少了 25.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 182166 股公司股票，价值 5136957 美元。公司内部人士持有公司股票的 9.50%。</p>
</div><h2>Stoke Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Stoke Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc.是一家早期阶段的生物制药公司，致力于开发治疗美国严重遗传疾病根本原因的药物。该公司利用其专有的核基因输出靶向增强技术，开发反义寡核苷酸，以选择性恢复蛋白质水平。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Stoke Therapeutics</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Stoke Therapeutics</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>如何投资 FAANG 股票</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RPSw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=STOK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Stoke Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Stoke Therapeutics 吗？</h2>
</div><p>Before you consider Stoke Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Stoke Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Stoke Therapeutics 并不在名单上。</p>
</div><p>While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Stoke Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

股票分析师为 Stoke Therapeutics 设定 2027 财年的收益预期